A5020861863- Hematopoietic Stem Cell Transplantation
- Neutropenia and Cancer Infections
- Antifungal resistance and susceptibility
- Acute Lymphoblastic Leukemia research
- Fungal Infections and Studies
- Blood disorders and treatments
- Immunodeficiency and Autoimmune Disorders
- Childhood Cancer Survivors' Quality of Life
- Polyomavirus and related diseases
- Cytomegalovirus and herpesvirus research
- Lymphoma Diagnosis and Treatment
- Pneumocystis jirovecii pneumonia detection and treatment
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Central Venous Catheters and Hemodialysis
- Blood groups and transfusion
- Viral-associated cancers and disorders
- Immune Cell Function and Interaction
- Neonatal Health and Biochemistry
- Mycobacterium research and diagnosis
- Autoimmune and Inflammatory Disorders Research
- Parvovirus B19 Infection Studies
- COVID-19 and healthcare impacts
- Hematological disorders and diagnostics
- Hepatitis B Virus Studies
Azienda Ospedaliera Universitaria Integrata Verona
2016-2025
University of Verona
2013-2024
Istituto Giannina Gaslini
2011-2024
Ospedale Regina Margherita
2006-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2024
IRCCS Materno Infantile Burlo Garofolo
2011-2024
Azienda Ospedaliera Universitaria Pisana
2024
ORCID
2024
Weatherford College
2022
Nicolaus Copernicus University
2016-2022
Primary hemophagocytic lymphohistiocytosis is a rare syndrome characterized by immune dysregulation and hyperinflammation. It typically manifests in infancy associated with high mortality.We investigated the efficacy safety of emapalumab (a human anti-interferon-γ antibody), administered dexamethasone, an open-label, single-group, phase 2-3 study involving patients who had received conventional therapy before enrollment (previously treated patients) previously untreated were 18 years age or...
A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers 47 countries to the 2014 survey. Trends include: continued growth transplant activity, more so Eastern European than west; a increase use haploidentical family donors (by 25%) and slower for unrelated donor HSCT. The cord blood as source has decreased again 2014. Main indications HSCT leukemias: 11 853 (33%; 96%...
Abstract The Fifth European Conference on Infections in Leukaemia (ECIL-5) convened a meeting to establish evidence-based recommendations for using tests diagnose Pneumocystis jirovecii pneumonia (PCP) adult patients with haematological malignancies. Immunofluorescence assays are recommended as the most sensitive microscopic method (recommendation A-II). Real-time PCR is routine diagnosis of PCP (A-II). Bronchoalveolar lavage (BAL) fluid best specimen it yields good negative predictive value...
Information on incidence, and factors associated with mortality is a prerequisite to improve outcome after hematopoietic stem cell transplantation (HSCT). Therefore, 55′668 deaths in 114′491 patients HSCT (83.7% allogeneic) for leukemia were investigated landmark analysis causes of death at day 30 (very early), 100 (early), 1 year (intermediate) 5 years (late). Mortality from all decreased cohort (1980–2001) 2 (2002–2015) post-transplant phases autologous HSCT. After allogeneic HSCT,...
The advances in hematopoietic cell transplantation (HCT) over the last decade have led to a transplant-related mortality below 15%. Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is life-threatening complication of HCT that belongs group diseases increasingly identified as transplant-related, systemic endothelial diseases. In most cases, SOS/VOD resolves within weeks; however, severe results multi-organ dysfunction/failure with rate >80%. A timely diagnosis critical...
Abstract The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based grading system IDSA. Trimethoprim/sulfamethoxazole given 2–3 times weekly is drug choice primary PCP adults (A-II) and children (A-I) should be during entire period at...
The objective of this analysis was to investigate prognostic factors that influence the outcome Epstein-Barr virus (EBV)-related posttransplant lymphoproliferative disorder (PTLD) after a rituximab-based treatment in allogeneic hematopoietic stem cell transplant (HSCT) setting. A total 4466 HSCTs performed between 1999 and 2011 19 European Group for Blood Marrow Transplantation centers were retrospectively analyzed PTLD, either biopsy-proven or probable disease. One hundred forty-four cases...
This intercontinental study aimed to gram-negative rod (GNR) resistance in hematopoietic stem cell transplantation (HSCT).GNR bacteremias occurring during 6 months post-HSCT (February 2014-May 2015) were prospectively collected, and analyzed for rates risk factors fluoroquinolones, noncarbapenem anti-Pseudomonas β-lactams (noncarbapenems), carbapenems, multidrug resistance.Sixty-five HSCT centers from 25 countries Europe, Australia, Asia reported data on 655 GNR episodes 704 pathogens 591...
The use of a cytomegalovirus (CMV)–seropositive unrelated hematopoietic stem cell transplant (HSCT) donor for CMV-seronegative patient results in reduced overall survival. HSCT seropositive survival after myeloablative conditioning. Background. (CMV)–seronegative allogeneic recipient is generally accepted. However, the importance serostatus CMV-seropositive patients controversial. Methods. A total 49 542 patients, 29 349 and 20 193 seronegative, were identified from European Group Blood...
A record number of 39 209 HSCT in 34 809 patients (14 950 allogeneic (43%) and 19 859 autologous (57%)) were reported by 658 centers 48 countries to the 2013 survey. Trends include: more growth than HSCT, increasing use sibling unrelated donors a pronounced increase haploidentical family when compared with cord blood for those without matched related or donor. Main indications leukemias, 11 190 (32%; 96% allogeneic); lymphoid neoplasias, 958 (57%; 11% solid tumors, 1543 (4%; 4% nonmalignant...
Background We analyzed the outcome of 100 patients with acquired severe aplastic anemia undergoing an alternative donor transplant, after immune suppressive therapy had failed.Design and Methods As a conditioning regimen, received either combination fludarabine, cyclophosphamide, antithymocyte globulin (n=52, median age 13 years) or this addition low dose (2 Gy) total body irradiation (n=48, 27 years).Results With follow-up 1665 765 days, actuarial 5-year survival was 73% for group that 79%...
Summary. This study aimed to ascertain whether extracorporeal photochemotherapy (ECP) is an effective treatment for paediatric patients with refractory graft‐versus‐host disease (GVHD). From January 1992 December 2000, 77 children (median age 8·6 years) either acute ( n = 33) or chronic 44) GVHD, resistant conventional immunosuppressive therapy, were treated ECP in four Italian hospitals. After ECP, GVHD involving skin, liver and gut responded completely 76%, 60% 75% of respectively. The...
<b>Background:</b> Osteopetrosis, a genetic disease characterised by osteoclast failure, is classified into three forms: infantile malignant autosomal recessive osteopetrosis (ARO), intermediate (IRO), and dominant (ADO). <b>Methods:</b> We studied 49 patients, 21 with ARO, one IRO, 27 type II ADO (ADO II). <b>Results:</b> Most ARO patients bore known or novel (one case) ATP6i (TCIRG1) gene mutations. Six had no mutations in ClCN7, the only so far recognised implicated, suggesting...